| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
INFLAMMATION AND INFLAMMATORY BOWEL DISEASE |
Division of Gastroenterology, Azienda Ospedaliera S Camillo-Forlanini, Rome, Italy
Correspondence to:
Correspondence to:
Dr C Prantera, Divisione di Gastroenterologia, Azienda Ospedaliera S Camillo-Forlanini, Via Portuense, 292, 00149 Roma, Italy;
prantera{at}tin.it
ABSTRACT
Background and aims: Experimental studies have shown that luminal bacteria may be involved in Crohn's disease. Probiotics are a possible alternative to antibiotics. The aim of this randomised placebo controlled study was to determine if Lactobacillus GG, given by mouth for one year, could prevent Crohn's recurrent lesions after surgery or to reduce their severity.
Methods: Patients operated on for Crohn's disease in whom all of the diseased gut had been removed were randomly allocated to receive 12 billion colony forming units of Lactobacillus or identical placebo for one year. Ileocolonoscopy was performed at the end of the trial or at the onset of symptoms. Endoscopic recurrence was defined as grade 2 or higher of Rutgeerts scoring system.
Results: Eight of 45 patients were excluded from the trial (three for non-compliance and five for protocol violations). Clinical recurrence was ascertained in three (16.6%) patients who received Lactobacillus and in two (10.5%) who received placebo. Nine of 15 patients in clinical remission on Lactobacillus (60%) had endoscopic recurrence compared with six of 17 (35.3%) on placebo (p=0.297). There were no significant differences in the severity of the lesions between the two groups.
Conclusions: Lactobacillus GG seems neither to prevent endoscopic recurrence at one year nor reduce the severity of recurrent lesions.
Keywords: Crohn's disease; probiotics; lactobacillus GG; gut bacteria; endoscopic recurrence
Abbreviations: CDAI, Crohn's disease activity index; LGG, Lactobacillus GG; cfu, colony forming units
Relevant Article
Gut 2002 51: 301.
This article has been cited by other articles:
|
|
 |
|
  C. Guzy, D. Paclik, A. Schirbel, U. Sonnenborn, B. Wiedenmann, and A. Sturm The probiotic Escherichia coli strain Nissle 1917 induces {gamma}{delta} T cell apoptosis via caspase- and FasL-dependent pathways Int. Immunol., July 1, 2008; 20(7): 829 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Corthesy, H. R. Gaskins, and A. Mercenier Cross-Talk between Probiotic Bacteria and the Host Immune System J. Nutr., March 1, 2007; 137(3): 781S - 790S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. de Vrese and P. R. Marteau Probiotics and Prebiotics: Effects on Diarrhea J. Nutr., March 1, 2007; 137(3): 803S - 811S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Prantera Probiotics for Crohn's disease: what have we learned? Gut, June 1, 2006; 55(6): 757 - 759. [Full Text] [PDF]
|
|
|
|
|
|
P Marteau, M Lemann, P Seksik, D Laharie, J F Colombel, Y Bouhnik, G Cadiot, J C Soule, A Bourreille, E Metman, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial Gut, June 1, 2006; 55(6): 842 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Caprilli, M A Gassull, J C Escher, G Moser, P Munkholm, A Forbes, D W Hommes, H Lochs, E Angelucci, A Cocco, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations Gut, March 1, 2006; 55(suppl_1): i36 - i58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Menard, D. Laharie, C. Asensio, T. Vidal-Martinez, C. Candalh, A. Rullier, F. Zerbib, F. Megraud, T. Matysiak-Budnik, and M. Heyman Bifidobacterium breve and Streptococcus thermophilus Secretion Products Enhance T Helper 1 Immune Response and Intestinal Barrier in Mice Experimental Biology and Medicine, November 1, 2005; 230(10): 749 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Dray and P. Marteau The Use of Enteral Nutrition in the Management of Crohn's Disease in Adults JPEN J Parenter Enteral Nutr, July 1, 2005; 29(4_suppl): S166 - S172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jenkins, S. Holsten, S. Bengmark, and R. Martindale Probiotics: A Practical Review of Their Role in Specific Clinical Scenarios Nutr Clin Pract, April 1, 2005; 20(2): 262 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Di Giacinto, M. Marinaro, M. Sanchez, W. Strober, and M. Boirivant Probiotics Ameliorate Recurrent Th1-Mediated Murine Colitis by Inducing IL-10 and IL-10-Dependent TGF-{beta}-Bearing Regulatory Cells J. Immunol., March 15, 2005; 174(6): 3237 - 3246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Furrie, S Macfarlane, A Kennedy, J H Cummings, S V Walsh, D A O'Neil, and G T Macfarlane Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial Gut, February 1, 2005; 54(2): 242 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W Kruis, P Fric, J Pokrotnieks, M Lukas, B Fixa, M Kascak, M A Kamm, J Weismueller, C Beglinger, M Stolte, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine Gut, November 1, 2004; 53(11): 1617 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H S Gill and F Guarner Probiotics and human health: a clinical perspective Postgrad. Med. J., September 1, 2004; 80(947): 516 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Menard, C Candalh, J C Bambou, K Terpend, N Cerf-Bensussan, and M Heyman Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport Gut, June 1, 2004; 53(6): 821 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Ghosh, D van Heel, and R J Playford Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut, May 1, 2004; 53(5): 620 - 622. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Reid, J. Jass, M. T. Sebulsky, and J. K. McCormick Potential Uses of Probiotics in Clinical Practice Clin. Microbiol. Rev., October 1, 2003; 16(4): 658 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jonkers and R. Stockbrugger Probiotics and inflammatory bowel disease J R Soc Med, April 1, 2003; 96(4): 167 - 171. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Garcia de Tena, L. M. Espinosa, M. Alvarez-Mon, G. Famularo, V. Trinchieri, C. De Simone, F. Marchetti, S. Martelossi, A. Ventura, F. Mohammed, et al. Inflammatory Bowel Disease N. Engl. J. Med., December 12, 2002; 347(24): 1982 - 1984. [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
